Ligand Targeted Nano-Medicine: Current Status and Translational Opportunity
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (30 July 2021) | Viewed by 436
Special Issue Editors
Interests: liposomes; targeted drug delivery; niosomes; nanoformulations; PLGA nanoparticles; micelles; thermoreversible gel; controlled release; ocular drug delivery
Special Issues, Collections and Topics in MDPI journals
Interests: nanodrug delivery; thermoreversible gel; ocular drug delivery; age-related macular degeneration; corneal delivery; polymeric nanoparticles; polymeric micelles; biomaterials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues,
Receptor-targeted and ligand-guided nano-medicine-based drug and gene delivery therapies have shown promise for the diagnosis, prevention and treatment of human ailments. Ligand targeted nano delivery systems have resulted in the site specific delivery of therapeutics to improve efficacy while reducing adverse effects because of reduced exposure to normal healthy cells. Specifically, nano or macroparticle-based drugs and genes have great potential in revolutionizing the therapeutic delivery field. Despite recent advances, translational applications of newer drug and gene delivery technologies to the clinic have a lower success rate. Therefore, there is an unmet need to address the critical aspects and gaps for translational application of these delivery systems. This Special Issue will address the current status in the development of ligand-targeted drug and gene delivery systems and their translational application for the diagnosis and treatment of the human diseases.
Dr. Priyanka Bhatt
Dr. Vijaykumar B. Sutariya
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted delivery
- nanoformulations
- site specificity
- ligand targeting
- biomaterial
- nanoparticles
- nanocarriers
- antibody–drug conjugate
- immunoliposomes
